KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

EPS

Last Annual Value

-2.85

3-Year CAGR

62%

5-Year CAGR

46%

10-Year CAGR

26%

KT

Kalaris Therapeutics Inc Competitors Analysis of EPS

KLRS · NASDAQ
CompanyEPS
CAGR 3Y
CAGR 5Y
CAGR 10Y
-2.85
N/AN/AN/A 
-0.24
N/AN/AN/A
-3.43
N/AN/AN/A
-0.70
N/AN/AN/A
-0.38
N/AN/AN/A
-2.36
N/AN/AN/A
-6.62
N/AN/AN/A
-1.90
N/AN/AN/A
-1.86
N/AN/AN/A
-50.83
N/AN/AN/A
1.53
121.9%N/AN/A
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7